In December 2018, two decades of research starting in the Langer Lab at MIT resulted in FDA approval of Inbrija, the first approved inhaled levodopa powder for Parkinson’s patients.

This same lab – led by the “Edison of Medicine,” Robert Langer – is now in collaboration with other leading research labs at MIT and poised to begin a significant research effort to take Parkinson’s research to the next level.

The Cure Now: PD group of CAP is now officially working with MIT in Cambridge, MA on this Parkinson’s research initiative that is unique, that differs from existing approaches, that potentially fills a gap in existing research – an “unmet need” - using nanotechnology and MIT-specific tools and methods that are found nowhere else.

This project ties together some of the world’s most productive research labs at MIT in an unprecedented collaboration between scientists that have already produced outcomes that are second-to-none.  These scientists are at the top of their fields, and will now join together as world-class researchers to do “something transformative” for Parkinson’s.  It’s an exciting time!

This MIT initiative is unlike other initiatives as it aims to develop new drugs, new scanning techniques, and new drug delivery devices that are designed to circumvent the blood-brain barrier and treat the areas of the brain directly affected by PD.

If you or someone you know has PD, you may be frustrated with the pace of research.  We believe current research deserves our support, BUT WE ALSO BELIEVE FUNDING OUT OF THE BOX RESEARCH IS IMPERATIVE.  The Parkinson’s Research Initiative at MIT is just that.

Learn how to get involved and make a monumental impact. Join our community of passionate supporters who are committed to helping patients gain rapid access to better treatments – and having a voice in the urgency and focus of research for disease-modifying treatments. 

To learn more about the research, about how to get involved and make a monumental impact, please go to Curenowpd.org